Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  1.50 0.93% 163.50 543,725 15:23:07
Bid Price Offer Price High Price Low Price Open Price
162.00 165.00 163.50 161.50 162.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 166.77 7.11 -0.88 174
Last Trade Time Trade Type Trade Size Trade Price Currency
18:11:39 O 12,750 163.082 GBX

Cello Health (CLL) Latest News (8)

More Cello Health News
Cello Health Takeover Rumours

Cello Health (CLL) Discussions and Chat

Cello Health Forums and Chat

Date Time Title Posts
03/7/202007:34Cello - solid prospects1,086
29/1/201516:56CELLO GROUP?9
12/1/200516:17Cello or EQI?-

Add a New Thread

Cello Health (CLL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-07-03 17:11:51163.0812,75020,792.96O
2020-07-03 17:11:01163.0812,75020,792.96O
2020-07-03 17:02:48163.0859,50097,033.79O
View all Cello Health trades in real-time

Cello Health (CLL) Top Chat Posts

Cello Health Daily Update: Cello Health Plc is listed in the Media sector of the London Stock Exchange with ticker CLL. The last closing price for Cello Health was 162p.
Cello Health Plc has a 4 week average price of 112p and a 12 week average price of 107.50p.
The 1 year high share price is 163.50p while the 1 year low share price is currently 101p.
There are currently 106,690,531 shares in issue and the average daily traded volume is 3,639,516 shares. The market capitalisation of Cello Health Plc is £174,439,018.19.
bargainbob: Poikka glad i introduced a little Fanny to the advfn boards and it boosted the share price to heights not seen before. Good luck reaching 150p
davebowler: Cenkos; Organic momentum continues Today’s largely in-line results were well flagged by January’s trading update, but there are notable beats on EPS, DPS and Net cash. The group continues its organically focused delivery, leveraging Signal’s digital capabilities into the healthcare space, alongside new office openings. This will continue Cello’s migration over time into a more healthcare-focused, US-centric and higher margin business. We feel the defensive nature and FCF potential of Cello are not fairly valued in the current share price.
qs99: Continued good moves....a great story really IMO given fund raise, more than required, implying more deals (+use of debt) in future, tech focus in new broker notes, share price already 10%+ above placing price as well received....more to come IMO as reckon from this share price rise, there are a few who are buying into story....DYOR and gla
davebowler: FinnCap; Post the placing, Cello has net cash and, with an acquisition, has signalled its intent to invest for growth now that the VAT issue is firmly behind it. We continue to believe Pulsar, its social media tool, is in the share price for free, but also increasingly that Cello has developed a widening range of technologies that are performing well and support good profit growth potential. Cello is moving away from an ‘hours utilised and billed' type model towards a technology-backed model, a more valuable proposition.
zipstuck: The oversubscribed placing underpins the share price and there is all to play for in 2017
davebowler: Price: 100.0p Target Price: 132.0p Cello has confirmed the Group delivered an encouraging trading performance in 2016 and 2017 begins with good momentum from existing and new clients. Most importantly for our buy case, there has been an ‘excellent performance’ from Cello’s growing suite of software-enabled products. We make no changes to our forecasts and continue to believe the share price significantly undervalues the technologies Cello has developed, most notably Pulsar its social media analytics tool which we believe is in the price for free.
davebowler: Finncap; Price: 106.0p Target Price: 132p Cello has an overlooked and potentially significantly undervalued asset that is now out of development phase. Cello Pulsar is a social media analytics tool that has significant points of difference to the competition. In the right hands, social media data can inform, direct and optimise marketing campaigns but to date its usage has been constrained by early-stage science and customer unfamiliarity. Competitors in this area have individually raised nearly half of Cello's market cap, emphasising Pulsar’s potential to add very material value to the share price. We initiate at Buy.
qs9: nice IMO to see directors taking advantage of recent share price weakness...
hpcg: I think its a bit chicken and egg with regards to liquidity / spread; its thinly traded which puts people off. If they participated then there would be more liquidity! However I'm speculating as to the motives of others, and it could just be that investors want to see more prolonged evidence of progress. If the company does the business the share price will as well.
glasshalfull: Signs of life in the CLL share price in the last few sessions. If recent years are anything to go by then there is a very strong chance of a trading update anytime now. Trading statements released on the following dates:- 3rd July 2009 4th July 2008 12th July 2007 3rd July 2006 2010 market updates 19th January 2010 - pre-close trading update indicated that there were signs of improvement in markets. 16th March 2010 preliminary results confirmed improvement, "Cello has strong revenue pipelines in Research and Consulting and Tangible has also seen a marked increase in levels of new business activity." 17th May 2010 - AGM statement noted "The Group has therefore performed strongly during the first quarter of 2010. While there remains economic uncertainty, we are growing in confidence about the Group's performance." So, given that guidance in 2010 has been of improving markets and strong performance (so far) I'm hopeful that CLL will be in line with market forecasts at the very least....and there's always a possibility that they may be ahead. Worth reiterating m my earlier post - 364 Altium snippet on AGM update "...we continue to view the group's stock as substantially undervalued and would cite: (a) the quality of its underlying operating assets, (b) robust financials (debt well within long-term facilities of £17m), and (c) earnings growth potential as a recovery in research and marketing spend plays through a scaleable cost base, as key attractions. We are nudging up our target price from 46p to 49p (an undemanding 7x FY 2010E PER / c.48% upside) to reflect the encouraging momentum highlighted above and reiterate our BUY recommendation." Regards, GHF
Cello Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Cello Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200704 16:33:39